Clinical Trial Update: ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1 [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ACVBP plus Rituximab vs CHOP plus Rituximab in patients with diffuse large B-cell lymphoma and an age-adjusted IPI of 1 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• ACVBP regimen
• CHOP regimen
• Rituximab (rituximab)

Snippet

Sponsor: Lymphoma Study Association | Conditions: Diffuse Large-Cell Lymphoma | Phase 3 | Status: COMPLETED